A study by Guerrero-Preston et al., (2014) further substantiates the antitumor activity of the PAX5/Tp53 axis by demonstrating that PAX5 promoter hypermethylation in head and neck squamous cell carcinoma results in inadequate Tp53 activation [76]. This evidence concerns the gene PAX5 and head and neck squamous cell carcinoma.